Nektar Therapeutics (NKTR) Posts Q3 Loss of $0.21, Sales Top Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $39.56 -0.88%
Revenue Growth %: -13.0%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
AEHR, VFS, CMTL, More
Revenue Growth %: -13.0%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.21), $0.16 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $15.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi reiterates buy rating on Nektar Therapeutics with $151 target
- Taylor Devices (TAYD) Misses Q1 EPS by 79c
- New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
